On February 5, 2015, Blinn, James Robert; Flick, Andrew Christopher; Wennerstaal, Goeran Mattias; Jones, Peter; Kaila, Neelu; Kiefer, James Richard, Jr.; Kurumbail, Ravi G.; Mente, Scot Richard; Meyers, Marvin Jay; Schnute, Mark Edward; Thorarensen, Atli; Xing, Li; Zamaratski, Edouard; Zapf, Christoph Wolfgang published a patent.Safety of 2-Chloro-5-isopropylpyrimidine The title of the patent was Preparation of N-heteroaryl amides as RORC2 inhibitors. And the patent contained the following:
The present invention provides compounds I-VII [Y = H, halo, CN, etc.; R1 = H, alkyl, hydroxyalkyl, haloalkyl; X = NHC(O)R2, NHC(O)NHR2, NHSO2R2, etc.; R2 = alkyl, cycloalkyl, aryl, etc.; W = N-substituted 4-piperidinyl, 3-piperidinyl, 3-pyrrolidinyl, 3-azetidinyl], pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds I-VII and pharmaceutical compositions Ninety-five compounds I-VII were prepared E.g., a multi-step synthesis of VIII, starting from 5-nitroindole and tert-Bu 4-oxopiperidine-1-carboxylate, was described. Exemplified compounds I were evaluated for RORC2 activity (data given). The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Safety of 2-Chloro-5-isopropylpyrimidine
The Article related to heteroaryl amide preparation rorc2 inhibitor immune inflammatory disorder treatment, antiinflammatory immunomodulator antiarthritic antirheumatic heteroaryl amide preparation interleukin17 decrease, sulfonamide urea amide heteroaryl indolyl pyrrolopyridinyl preparation rorc2 inhibitor and other aspects.Safety of 2-Chloro-5-isopropylpyrimidine
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia